Zoetis Inc. (ZTS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Parsippany, NJ, United States. Der aktuelle CEO ist Kristin C. Peck.
ZTS hat IPO-Datum 2013-02-01, 13,800 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $51.12B.
Zoetis Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, and diagnostic products for livestock and companion animals. The company serves cattle, swine, poultry, fish, sheep, dogs, cats, and horses through a comprehensive portfolio including vaccines, anti-infectives, parasiticides, pain management products, dermatology treatments, and medicated feed additives. Additionally, Zoetis provides diagnostic solutions such as point-of-care blood and urine analysis, rapid immunoassay tests, and reference laboratory services, along with nutritional and precision animal health products. The company distributes its products through veterinarians, livestock producers, retail outlets, and third-party veterinary distributors. Founded in 1952 and headquartered in Parsippany, New Jersey, Zoetis operates internationally to serve the global animal health market.
